Evidence Hub

Improvements in COPD Symptoms with Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial

C. Vogelmeier, I. Boucot, E. Kerwin, L. Bjermer, P. Jones, I. Naya, L. Tombs, C. Compton et al.

2020

Abstract

1Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Germany, Member of the German Center for Lung Research (DZL), Marburg, Germany; 2Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK; 3Clinical Research Institute of Southern Oregon, Medford, OR, USA; 4Respiratory Medicine and Allergology, Lund University, Lund, Sweden; 5Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK (at the time of the study); 6Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK (at the time of the study) and RAMAX Ltd, Bramhall, Cheshire, UK; 7Precise Approach Ltd, contingent worker on assignment at GSK, Stockley Park West, Uxbridge, Middlesex, UK; 8Respiratory Clinical Sciences, GSK, Collegeville, PA, USA, and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 9Centre de Pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Québec, Canada

How strong is the evidence?

Evidence Hub reads this as a secondary / pooled analysis. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free